---
title: Mechanistic Model — Case Study
---

# Integrated Mechanistic Overview

This document consolidates symptom descriptions, physiologic hypotheses, and supporting laboratory findings into a concise, clinician-oriented model. Redundant “session” annotations and lay phrasing have been replaced with standardized medical terminology.

---

## Neuroendocrine–Autonomic Dysregulation

Episodes appear to originate from **dysregulated adrenergic drive**, producing recurrent surges of catecholamines with excessive β-adrenergic and α-1 receptor stimulation. This results in:

- Paroxysmal **hypertension** and **tachycardia**
- **Anxiety, agitation, hypervigilance**, and **insomnia**
- **Migraine-like headaches** with photophobia and phonophobia
- **Peripheral vasoconstriction** followed by **rebound vasodilation**, contributing to dependent edema (notably in the postoperative foot)
- **Hyperglycemia** secondary to stress-induced hepatic gluconeogenesis

Persistent sympathetic activation amplifies metabolic demand while impairing restorative parasympathetic tone, leading to non-restorative sleep and cumulative fatigue.

---

## Neuroimmune and Mast-Cell Activation Axis

Clinical pattern aligns with **mast-cell activation syndrome (MCAS)**, characterized by histamine, leukotriene, and prostaglandin release. Triggers include high-histamine foods and elevated folate load, both observed to precipitate identical flares.

**Pathophysiology:**
1. Catecholamine excess primes mast-cell degranulation via β₂-adrenergic pathways.  
2. Histamine and cytokines increase vascular permeability → edema, flushing, orthostasis.  
3. Reactive oxygen species (ROS) and methylation demand rise, consuming SAMe, PLP, and DAO cofactors.  

Mitigation with **clonidine**, **dual H₁/H₂ blockade**, **DAO supplementation**, **creatine**, and **methylated B-complex** reduces frequency and intensity of flares by blunting adrenergic signaling and replenishing methyl donors.

---

## Mitochondrial and Bioenergetic Impairment (Working Model)

Recurrent stress-associated episodes are hypothesized to involve **transient mitochondrial dysfunction** with impaired oxidative phosphorylation and ATP depletion in neural, hepatic, and skeletal muscle tissues.

**Proposed sequence:**
1. Catecholamine surge → intracellular **Ca²⁺ overload** and mitochondrial ROS production.  
2. Oxidative and methylation stress impair complexes I–III, compromising NAD⁺/FADH₂ turnover.  
3. Histamine and inflammatory mediators further **uncouple oxidative phosphorylation**.  
4. Resultant **bioenergetic failure** manifests as cognitive “brownout,” ataxia, and post-exertional fatigue.  
5. **Creatine, SAMe, and DAO** mitigate this by stabilizing methylation balance and reducing ROS, decreasing flare frequency and intensity.

---

### Corroborating Laboratory Pattern (Macrocytic / Alcoholic-Type Biochemical Signature)

Laboratory data demonstrate a **macrocytic “alcoholic-pattern”** without alcohol exposure:

- **AST > ALT** with normal γ-GT  
- **Macrocytosis (↑ MCV)**  
- **Low ALP and plasma phosphate**  
- **Low PLP (vitamin B₆) activity**

This constellation is consistent with **mitochondrial and hepatic oxidative stress** causing **secondary B₆ deficiency** and impaired transaminase recycling. Functional PLP depletion disrupts cystathionine β-synthase, transaminases, and neurotransmitter synthesis, contributing to cognitive dysfunction and mood lability.

Correction with methyl-B complex and creatine has correlated with improved recovery kinetics and reduced episode severity.

---

## Integrated Summary

The patient’s phenotype represents a self-reinforcing loop of **adrenergic overactivation → mast-cell mediator release → mitochondrial decompensation**, modulated by nutritional cofactor status.  
Therapeutic emphasis should remain on:
- Reducing adrenergic and inflammatory load  
- Maintaining methylation equilibrium  
- Supporting mitochondrial function  
- Monitoring B-vitamin and phosphate status
